I think the main point of stopping a trial early is not really to allow patients switch to the treated arm, but to allow all the other thousands patients get a more effective treatment as early as possible. But if they do not do an efficacy review, how can they recommend an early stop? By guessing?
News 
Market Data 
Discover 
